Category: Press Releases

Stockholm, Copenhagen, Scandinavia — Stratipath and Visiopharm, two global leaders in AI-based precision cancer diagnostics, today announced a strategic collaboration to combine their regulatory compliant solutions for enhanced breast cancer diagnostics. The joint initiative will be presented at the upcoming European Congress of Pathology (ECP) in Vienna, October 2025.

Over the years, Visiopharm has established itself as a global leader for AI-based biomarker scoring in diagnostic histopathology. Stratipath’s flagship prognostic AI solution, Stratipath Breast, has gained clinical adoption as a cost-efficient, faster alternative to traditional genomic tests for risk stratification of breast cancer patients.

The adoption of digital pathology is accelerating, with increasing recognition of the importance of combining complementary tools to improve and streamline treatment decisions. Numerous scientific investigations have found considerable variability of biomarker and grade assessment in and between pathology laboratories, and that may have serious consequences for individual treatment decisions. In parallel, most patients do not have access to expensive gene expression testing for risk prediction of ER+ HER2- breast cancers. By teaming up, Stratipath and Visiopharm can deliver comprehensive digital assessments in early breast cancer.

Bring clarity at first Multidisciplinary Team (MDT) meeting

Together, the solutions create a more actionable first-MDT pathway for early breast cancer: Complete accurate ER/PR, HER2 (including low/ultralow) and Ki-67 scoring, then generate a rapid, affordable risk score – reducing reliance on additional molecular assays with long turnarounds.

1. Visiopharm’s HER2 algorithm helps avoid unnecessary IHC 2+ reflex ISH/FISH so HER2 is ready on time.

2. Stratipath Breast, validated in HR+/HER2- cohorts, provides immediate prognostic stratification and reduces the need for costly and time-consuming gene expression tests.

3. As the therapeutic landscape expands (e.g., HER2-low/ultralow agents and adjuvant CDK4/6 inhibitors where Ki-67 can inform eligibility), a complete biomarker profile plus AI prognostication lets MDTs tailor each patient’s plan without risking delays.

”Modern healthcare requires fast and cost-efficient solutions with improved diagnostic accuracy” says Johan Hartman, professor of tumor pathology at Karolinska Institutet and Chief Medical Officer at Stratipath. “Bringing automated biomarker assessment and AI-based prognostication together means more patients can be sub-categorized accurately and on time at the first MDT, supporting confident treatment decisions.”

Delivering Faster, More Accessible Precision Diagnostics

Both Visiopharm’s diagnostic algorithms and Stratipath Breast are regulatory approved medical devices, enabling immediate clinical use. By combining these applications, pathology departments can deliver faster, more precise results – reducing overtreatment, undertreatment, and healthcare costs, while ensuring broader access to precision medicine.

“No single algorithm solves modern pathology; it’s a puzzle of complementary tools. Put the right ones together and 1+1 adds up to more than 2.” says Jeppe Thagaard, Scientific Director at Visiopharm. “Working with partners like Stratipath reflects our principle: measurable patient benefit and a simple, sustainable way for labs to pay for it.”

“As an active pathologist, I focus on ensuring these tools work seamlessly in clinical practice. Stratipath Breast represents the future of prognostic testing, integrated into digital pathology workflows alongside applications for automatic biomarker assessment. Combining them will save time, resources, and ultimately improve patient treatment decisions,” says Johan Hartman , Professor of pathology at Karolinska Insitutet and CMO at Stratipath.

Next Steps

As a first step, Stratipath and Visiopharm will initiate joint case studies at selected hospitals, mapping how the two applications can be combined in daily pathology practice.

The concept will be showcased in more detail at the Visiopharm booth during ECP 2025 in Vienna with results expected to be presented later this year.

Pathology and oncology departments interested in participating in these studies or adopting the combined solution are encouraged to reach out for further discussions.

About Stratipath

Stratipath is an AI company dedicated to revolutionising cancer treatment decisions and enhancing patient outcomes by assisting physicians in delivering optimal treatment to every patient. Stratipath’s pioneering solutions and AI-based precision diagnostic software platform transform tissue sample analysis, enabling breakthrough insights for enhanced and faster patient stratification across healthcare, clinical trials, and drug development. By expanding the reach of precision medicine, Stratipath aims to make this advanced healthcare approach accessible to a wider patient population. Founded as a spin-out of Karolinska Institutet in Stockholm, Sweden, Stratipath is built upon years of groundbreaking research and development. For more information, please visit www.stratipath.com.

About Visiopharm

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

For more information visit visiopharm.com.

Document ID:  17474_09_2025

Albuquerque, NM and Hørsholm, Denmark — Indica Labs and Visiopharm today announce the successful integration of Visiopharm’s Discovery image analysis software into Indica’s collaborative image management platform, HALO Link. The integration will enable laboratories to create a customized digital pathology ecosystem optimized for their unique image analysis and collaboration needs.

“We are excited to deliver this combined solution to our customers in collaboration with Visiopharm,” said Steven Hashagen, CEO of Indica Labs. “The fully integrated solution allows for a more seamless user experience when working between Discovery and HALO Link, enhancing efficiency and freeing users to focus on their next discovery.”

“The integration with HALO Link reflects our firm commitment to remaining platform-agnostic across staining systems, scanners and image management systems,” said Michael Grunkin, CEO of Visiopharm. “Indica Labs has rapidly established itself as a key player in the IMS space, and we are very pleased to offer our joint customers a streamlined experience that brings together Indica’s collaborative platform with Visiopharm’s advanced AI-driven image analysis.” 

The integration, available as a paid add-on with HALO Link 4.1, enables viewing of annotations, regions of interest (ROI), image markups, and analysis summary results generated in Discovery within HALO Link. HALO Link preserves the annotation layers and colors from Discovery, displays ROI and labels as interactive markups, streamlining viewing, and organizes analysis summary results in the image’s analysis tab. The integration functions with all image types supported by the platforms, as long as the image exists in both the HALO Link and Discovery databases.

HALO Link is a browser-based hub for pathology that helps research organizations worldwide safely and securely manage, share, and analyze digital slides and data. The platform offers seamless collaboration and limitless data organization with robust search capabilities. HALO Link natively integrates with HALO® and HALO AI, and its powerful API enables integration with LIS | LIMS systems, compatible third-party image analysis platforms, such as Discovery, and other third-party databases.

Visiopharm’s Discovery software enables users to explore complex tissue data intuitively and customize analyses to fit their specific experimental needs. Its advanced exploratory capabilities enhance analysis accuracy in complex tissue samples. The ability to develop custom deep-learning-based segmentation algorithms, which can account for both cellular and nuclear morphology, enables precise quantification of biomarkers.

The HALO Link 4.1 release is currently available. Contact support@indicalab.com to initiate a software upgrade.

About Indica Labs
Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organizations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery.

For more information, please visit https://indicalab.com or contact info@indicalab.com.

About Visiopharm 

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

For more information visit visiopharm.com.

Indica Labs Media Contact:
Adam Smith
adam@indicalab.com

Visiopharm Media Contact:
Johanne Louise Brændgaard 
jlb@visiopharm.com

Document ID: 16773_april 2025 

Streamlined multiplex immuno-profiling capabilities and AI-driven image analysis will be demonstrated during a poster presentation at AACR 2025.

Danvers, MA, USA — Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, and Visiopharm, a global leader in AI-driven precision pathology software, today announced a strategic partnership to advance spatial biology research. The collaboration enables more streamlined analysis of images generated using the SignalStar^® Multiplex IHC technology in Visiopharm’s Phenoplex software, helping researchers to more efficiently interrogate cellular interactions in the tumor microenvironment and streamline biomarker discovery and analysis.

“As multiplexed spatial biology assays become more flexible and robust, they must be paired with powerful, AI-driven image analysis solutions to truly uncover meaningful insights,” says Roberto (Roby) Polakiewicz, PhD, Chief Scientific Officer at CST. “We’re excited to partner with Visiopharm to provide researchers with a comprehensive toolbox of proven solutions so they can conduct advanced analyses of the tumor microenvironment with confidence.”

Through the partnership, CST and Visiopharm will deliver multiplexed biomarker staining, signal amplification, and data annotation and analysis capabilities, enabling spatial biology researchers to uncover actionable insights about disease progression and therapeutic response.

“At Visiopharm, we are committed to empowering researchers with AI-driven image analysis solutions that unlock the full potential of spatial biology,” said Regan Baird, PhD, Chief Research Solutions Officer at Visiopharm. “By combining CST’s cutting-edge multiplex IHC technology with our advanced Phenoplex software, we are enabling scientists to extract deeper, more precise insights into the tumor microenvironment. This partnership represents a significant step forward in accelerating biomarker discovery and advancing precision medicine.”

Visiopharm is a world leader in AI-based image analysis and workflow standardization, and CST offers best-in-class antibody technology for interrogating complex biological systems while maintaining their spatial context and tissue architecture. By combining the highly flexible antibody panels in the SignalStar Multiplex IHC assay with powerful AI-driven software from Visiopharm, biopharma researchers can confidently generate and analyze spatial data of the tumor microenvironment using a high-throughput method.

To demonstrate how CST and Visopharm’s capabilities in multiplex immuno-profiling can be leveraged together, the companies are presenting a poster at The American Association for Cancer Research (AACR) Annual Meeting 2025.

Poster:Spatial analysis of the DLBCL tumor microenvironment via the novel SignalStar^® multiplex immunohistochemistry assay
Authors: Jennifer Ziello, Shuling Zhang, Sarah Klein, Derek Papalegis, Lily Vu, Gabriella Spang, Arvin Ruiz and Giorgio Inghirami

To learn more, visit CST at AACR 2025 at booth #809 or stop by poster number 24 in the Spatial Proteomics and Transcriptomics 1 poster session.

About Cell Signaling Technology
Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our customers, our communities, and our planet. cellsignal.com 

About Visiopharm 

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

For more information visit visiopharm.com. 

CST Media and Press 

Rebecca J. Reppucci, MBA 
Cell Signaling Technology, Inc. 
Senior Director, Global Marketing Communications 
Phone: +1-978-880-3334 
Email: marketingpr@cellsignal.com 

ID: 16755_03_2025

Hørsholm, Denmark — Visiopharm, a world leader in AI-driven precision pathology, is thrilled to become a preferred partner to PathAI with the integration of its precision pathology APPs into the AISight^Ⓡ1 Image Management System (IMS). This partnership underscores Visiopharm’s commitment to transforming diagnostic and translational pathology workflows by enabling PathAI’s AISight IMS users to analyze images with unparalleled accuracy and speed.

Visiopharm offers a comprehensive suite of diagnostic APPs, including a breast panel (HER2, ER, PR, metastasis detection, and Ki-67), and a non-small cell lung cancer (PD-L1) APP. These APPs are IVDR-cleared for use in the EU and UK and designated for research use in other regions. These tools will empower pathology laboratories with high-performance algorithms designed to streamline workflows and enhance diagnostic precision.

PathAI’s AISight IMS is designed to enhance interoperability and efficiency in digital pathology. Laboratories using AISight can seamlessly access a diverse portfolio of digital pathology algorithms from leading global AI providers, including Visiopharm. Pathologists will benefit from rich visual support, including AI-generated overlays and embedded quantitative results, driving more informed decision-making and differentiated workflows.

“We are excited to collaborate with Visiopharm and integrate their leading AI image analysis technologies into our AISight platform,” said Andy Beck, CEO of PathAI. “This partnership reinforces our mission to provide pathologists with comprehensive, state-of-the-art tools that enhance precision and increase workflow efficiency in the pathology laboratory. By incorporating Visiopharm’s innovative solutions, we are broadening access to top-tier AI capabilities, ultimately driving better patient outcomes and setting a new standard in digital pathology.”

Michael Grunkin, CEO of Visiopharm, expressed his enthusiasm about the partnership: “We are delighted to collaborate with PathAI to bring our portfolio of fully automated AI-driven diagnostic and translational solutions for breast and lung cancer to a broader audience. Our commitment is to expand access to precision pathology on leading platforms. Becoming ​​​​a preferred partner for PathAI’s AISight Image Management System is an important step towards this goal. With our platform-agnostic technology designed for seamless integration, we look forward to working closely with the PathAI team to accelerate the adoption of digital pathology worldwide, ultimately enhancing lab efficiency and improving the quality of patient care.”

​​Pathology laboratories worldwide are invited to experience the power of Visiopharm’s precision pathology APPs on PathAI’s AISight IMS. To schedule a demonstration of the APPs, please contact us at https://visiopharm.com.upd.mtra.in/. ​​

​​​​​ 

​​​¹AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK​​ 

About Visiopharm 

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

For more information visit visiopharm.com. 

About PathAI
PathAI is a global leader in AI-powered digital pathology solutions, dedicated to improving operational efficiency in pathology labs worldwide. Through its innovative technology and strategic partnerships, PathAI is shaping the future of medical diagnostics and advancing patient care across the globe.

Los Angeles, CA – Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology, is pleased to announce a strategic partnership with Visiopharm, a global leader in AI-driven precision pathology software. This collaboration brings together MI’s clinical-grade HCR™ platform with Visiopharm’s Oncotopix® Discovery software, empowering users with a highly flexible, deep learning approach to precise and efficient image analysis for RNA-ISH assays.

MI’s class-leading HCR™ Pro RNA-ISH assay, lauded for making protease-free sample preparation the standard for RNA-ISH, provides unparalleled specificity and sensitivity in RNA detection and enables seamless integration with existing IHC/IF workflows. When combined with Oncotopix® Discovery, researchers can analyze chromogenic and fluorescent HCR™ Pro RNA-ISH and HCR™ Pro RNA-ISH + IHC/IF co-detection images with more precise segmentation and spot counting, ensuring accurate gene expression profiling in even the most challenging samples.

“Our North Star at MI is to set bioimaging assays to a true ‘clinical-grade’ standard, focusing on performance, robustness, and accessibility,” said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. “Partnering with Visiopharm reflects our shared drive to delivering clinical-grade assays, paired with world-class analysis tools that empower pathologists and support decision-making. We’re thrilled to kickstart this journey with the team at Visiopharm to bring new possibilities to RNA-ISH.”

Visiopharm’s Oncotopix® Discovery software enables users to explore complex tissue data intuitively and customize analyses to fit their specific experimental needs. Its advanced exploratory capabilities enhance analysis accuracy in complex tissue samples. The ability to develop custom deep-learning-based segmentation algorithms, which can account for both cellular and nuclear morphology, enables more precise quantification of RNA. This marks a significant improvement over traditional methods, which often struggle with complex or irregular structures, such as anuclear or multinucleate cells, leading to missed or inaccurate counts.

“At Visiopharm, our mission is to empower researchers with advanced tools that deliver unmatched precision in image analysis,” said Regan Baird, Senior Vice President, Commercial Strategy Deployment of Visiopharm. “Partnering with Molecular Instruments allows us to elevate the standard of RNA-ISH analysis, integrating our Oncotopix® Discovery software with MI’s HCR™ technology to provide researchers with an unprecedented level of accuracy and efficiency. We are excited to collaborate and advance the field of precision pathology, accelerating breakthroughs in disease research and diagnostics.”

This partnership marks a pivotal advancement in research, combining high-performance, clinical-grade RNA-ISH with sophisticated image analysis. Together, we are equipping scientists to drive breakthroughs in disease studies, offering deeper insights into gene expression and protein interactions. By integrating our innovative technologies, we aim to accelerate discoveries across translational medicine, where accurately and precisely understanding gene and protein expression are essential.

About Visiopharm:  

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.  

For more information visit visiopharm.com.

About Molecular Instruments:  

Molecular Instruments® (www.hcrimaging.com) develops and synthesizes molecular kits powered by the breakthrough HCR™ imaging platform for applications in academic research, drug development, synthetic biology, and clinical pathology and diagnostics.

Hørsholm, Denmark — The University Medical Center Groningen (UMCG) based in the Netherlands is pleased to announce a significant strategic partnership with Visiopharm, a leading global provider of digital pathology solutions, for the coming five years. This collaboration represents an exciting step towards advancing the clinical implementation of AI-driven Precision Pathology.

The partnership revolves around multiple areas of cooperation, including the introduction of a state-of-the-art, automated, AI-based image analysis workflow for digital pathology built upon Visiopharm’s Oncotopix® and Qualitopix® platforms. This comprehensive workflow includes automatic slide quality assessment, continuous stain quality assessment, and biomarker quantification with the overarching objective of enhancing precision within laboratory operations.

The UMCG as a reference center for IHC Precision Pathology

A key initiative of this partnership is the establishment of the UMCG as a reference center. This center is not just a hub of technological innovation but also a living showcase demonstrating the significant impacts of AI-driven precision pathology on the standardization of diagnostic processes and the subsequent elevation of patient care standards. The UMCG is committed to not only adopting these advanced practices but also to meticulously quantifying their benefits and sharing these insights with the global clinical pathology community. The partnership with Visiopharm is in complete alignment with UMCG’s objective of data-driven research, data quality, and, ultimately, improved patient outcomes.

“By joining forces with Visiopharm, we are set to demonstrate the concrete benefits and transformative power of AI in precision pathology,” said Dr. Bert van der Vegt, Clinical Pathologist and lead of the Digital Computational Pathology Unit at UMCG. “As a reference center, we’re excited about the opportunity to share our journey and experiences, showcasing the tangible improvements in standardization and patient care that this technology brings.”

Visiopharm, a trusted name in the field of digital pathology, is equally enthusiastic about this partnership. “UMCG’s dedication to advancing precision pathology, and thereby optimal treatment decisions, perfectly aligns with our corporate mission. We look forward to our partnership and the opportunity to further document the benefits for diagnostic pathology laboratories seeking to implement precision pathology,” commented Dirk Vossen, Chief Diagnostic Officer at Visiopharm.

For clinical pathology laboratories considering the adoption of digital pathology, this private-partnership represents the epitome of innovation and progress. “UMCG and Visiopharm are working collaboratively to usher in transformative changes by offering enhanced data accuracy, operational efficiency, and improved patient care” adds Jacko Duker, project leader Digital and Computational Pathology at UMCG.

For further details about UMCG’s and Visiopharm’s strategic partnership, please visit

About Visiopharm 

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China. 

For more information visit visiopharm.com.

About UMCG 

The University Medical Center Groningen (UMCG) is one of the largest hospitals in the Netherlands. More than 12,000 employees work together on care, research, training, and education with the common goal of building the future of health. The UMCG offers complex, academic hospital care. It strives to do this better every day, constantly pushing the boundaries of diagnostics and treatments. The UMCG makes use of knowledge, research, and innovative solutions, as well as offering future-oriented education and training for healthcare professionals. Long-term partnerships build a healthcare landscape that is ready for the future. 

The UMCG researchers are pioneers in research who work on relevant research topics and are provided with a broad range of top-notch research facilities. The groundbreaking work of leading national and international researchers makes the UMCG a pioneering center for medical research. 

Role of the UMCG Innovation Center  

The UMCG Innovation Center has been instrumental in setting up the partnership, facilitated the work on innovative pathology solutions, and continues to support the collaboration.